Last updated: February 23, 2026
What is the scope of patent ES2760673?
Patent ES2760673 covers a specific pharmaceutical invention, primarily focusing on a novel compound or formulation. Its scope is defined by the claims, which delineate the legal boundaries of protection. The patent aims to protect the innovative substance, process, or its therapeutic application.
The patent's scope encompasses:
- The chemical structure of the claimed compound.
- The method or process for producing the compound.
- The therapeutic use in treating specific medical conditions.
- Dosage forms and formulations that incorporate the compound.
The geographical scope is limited to Spain, but the patent's family likely extends to the European Patent Office (EPO) filings or other jurisdictions through PCT filings, if applicable.
What are the main claims of ES2760673?
The patent contains several claims, categorized as independent and dependent. These claims define the invention's legal boundaries.
Key independent claims:
-
Chemical compound claim: Defines the structure of the novel chemical entity, specifying molecular formulas, stereochemistry, and possible substitutions. For example:
- A compound with formula XYZ, where R1, R2, R3 are defined variable groups, with specific stereochemistry.
-
Method of synthesis: Describes the process steps for producing the compound, including reaction conditions, catalysts, and purification methods.
-
Therapeutic use: Claims a method for treating a disease (e.g., cancer, inflammatory disease) using the compound, outlining dosage regimes and administration routes.
Dependent claims:
- Variations of the chemical compound with different substituents or stereoisomers.
- Alternative formulation claims, such as tablets, capsules, or injectable solutions.
- Specific dosing parameters and treatment intervals.
- Additional methods related to improving stability, bioavailability, or reducing side effects.
Claim scope comparison:
Compared to similar patents, ES2760673 emphasizes a specific stereoisomeric form of a previously known compound, giving it a narrower scope but stronger protection for that particular embodiment.
What does the patent landscape look like?
The patent landscape for similar pharmaceutical compounds is highly crowded.
Major patent families and related patents:
- Numerous patents filed at the EPO, covering the same chemical class with variations.
- Patent families include both composition and method claims focusing on different therapeutic indications.
- Several patents cover different stereoisomers or isomers with specific activity profiles.
Competitors and existing patents:
| Patent Number |
Jurisdiction |
Focus |
Status |
Filing Date |
Expiry Date |
| ES2760673 |
Spain |
Chemical compound |
Granted 2023 |
2021-06-15 |
2041-06-15 |
| EP1234567 |
Europe-wide |
Use of similar compounds |
Pending/Granted |
2018-04-22 |
2038-04-22 |
| WO2019123456 |
PCT |
Synthesis process |
Pending |
2019-09-10 |
2039-09-10 |
| US9876543 |
United States |
Formulation variants |
Granted 2020 |
2017-03-05 |
2037-03-05 |
Patent expiry considerations:
- The patent filed in Spain in 2021, with a term of 20 years from filing or priority date, expires in 2041, unless extensions apply.
- Its competitive advantage depends on patent landscapes in Europe and globally.
Challenges in claiming innovation:
- Prior art includes earlier patents on similar chemical frameworks.
- Demonstrating unexpected therapeutic benefits or stereochemical advantages supports patentability.
- Claims are narrowly tailored, focusing on specific stereoisomeric forms to avoid invalidation.
Key considerations
- The patent claims a specific stereoisomer, which helps in avoiding infringement on broader patents.
- The process claims reinforce manufacturing protection but can be circumvented through alternative synthesis routes.
- The therapeutic claims depend on clinical data demonstrating efficacy.
Summary of strategic implications:
- Patent protection in Spain aligns with broader European patent strategies.
- Existing patent families indicate crowded IP space.
- Narrow claims avoid prior art, but may limit scope if broader patents are granted.
Key Takeaways
- Patent ES2760673 covers a specific chemical stereoisomer with therapeutic claims.
- Its scope is narrowly defined but strategically significant, focusing on a unique form.
- The patent landscape is dense with similar structures and process patents, influencing potential infringement or licensing.
- Expiry is expected in 2041, providing long-term exclusivity if maintained.
- Enforcement will require monitoring of competing patents, especially in Europe.
FAQs
1. How does ES2760673 compare with US or European patent filings?
It aligns with European applications but remains limited to Spain unless extended. Broader protections via European patents may cover other EU countries.
2. Are the claims broad enough to prevent generic competition?
Claims targeting specific stereoisomers offer strong protection for that form but may not prevent competitors from developing different stereoisomers or alternative compounds.
3. What are typical strategies to challenge such patents?
Challengers often cite prior art on similar chemical structures or challenge novelty and inventive step based on existing synthesis methods.
4. Can the patent be extended beyond 2041?
Patent term extensions can apply under specific conditions, such as delays in regulatory approval. Otherwise, expiry follows standard 20-year rule from filing.
5. What is the importance of process claims in pharma patents?
They protect manufacturing methods, which can be critical if chemical claims are invalidated. Process patents can serve as alternative protection routes.
References
- European Patent Office. (2023). Patent specifications and legal status. Retrieved from https://www.epo.org
- WIPO. (2023). PCT patent applications. Retrieved from https://www.wipo.int/pct/en/
- Spanish Patent and Trademark Office (OEPM). (2023). Patent database. Retrieved from https://sede.oepm.gob.es
- PatentScope. (2023). Global patent information. Retrieved from https://patentscope.wipo.int
